Dr. Hans-Jürgen Hess

The Pintex Scientific Advisory Board also includes Dr. Brian Druker, Howard Hughes Medical Investigator, discoverer of Gleevec in collaboration with Novartis; Dr. Daniel Von Hoff, Director of the Arizona Cancer Center; Dr. Tony Hunter, a leader in the field of cellular signaling biology at the Salk Institute; Dr. Hans Hess, formerly Vice President of Chemistry at Pfizer; Dr. Jack Chabala, formerly Vice President of Chemistry at Merck; Dr. Hans Fliri, former head of Early Lead Discovery at Aventis; Dr. Joseph Noel, a world-renowned crystallographer at Salk; Dr. Gunter Fischer, preeminent enzymologist at the Max-Planck Institute; and Dr. Gordon Gill, Dean of Scientific Affairs at the University of California, San Diego.

Hans-Jurgen Hess, Ph.D. Dr. Hess is honored for his discovery of Pfizer's prazosin (Minipress®), the first of an important new class of antihypertensives. In 1963, when Dr. Hess of Pfizer Central Research began research on prazosin, high blood pressure was one of the world's most serious undertreated diseases, threatening millions of people. Then-available agents suffered from adverse side effects or they soon stopped working as patients developed tolerance, leading some patients to drop out of treatment because hypertension itself is without symptoms. The major existing antihypertensives interfered nonselectively with blood-pressure control mechanisms of the sympathetic nervous system, which affects many areas of body function, including blood pressure. To avoid these effects, Dr. Hess decided to focus on an agent that would act selectively with these control mechanisms.

BRANFORD, Conn., Oct. 4 /PRNewswire/ -- Cellular Genomics Inc. (CGI, http://www.cellulargenomics.com/) today announced that Hans Hess, Ph.D., and Jan Wasley, Ph.D., have been appointed to the Company's Scientific Advisory Board.
...
Dr. Hess is a former Vice President of Medicinal Products Research at Pfizer, Inc., and Dr. Wasley is the President of Simpharma, LLC, a drug discovery consulting firm with an international client base.
...
Dr. Hess was Vice President of Medicinal Products Research at Pfizer, leading the Pfizer Medicinal Chemistry effort and affiliated functions in the U.S. for many years.He also established and led the Pfizer drug discovery operations in Japan.He is the inventor of prazosin (Minipress®) and trimazosin (Cardovar®), major prototypical agents for the treatment of hypertension and prostatic hyperplasia, and headed the discovery efforts leading to the development of sulprostone (Nalador®), a prostaglandin analog licensed to Schering AG for obstetric and gynecological use, and pirbuterol (Maxair®), a beta-adrenergic agonist bronchodilator licensed to 3M Pharmaceuticals.He received the Pharmaceutical Manufacturers Association (PMA) Drug Discoverers Award for pioneering work on the discovery of prazosin and subsequent drug discovery leadership, and has been named inventor or co- inventor on approximately 100 issued U.S. patents.

"CGI has unique and compelling chemical genetic technologies for kinase drug discovery," said Dr. Hess."I am very much looking forward to working with their team as it moves forward in its drug discovery efforts."

Hans-Jürgen HessCellular Genomics Inc
...
Dr. Hess was Vice President Medicinal Products Research at Pfizer, leading the Pfizer Medicinal Chemistry effort and affiliated functions in the U.S. for many years.He also established and led the Pfizer drug discovery operations in Japan.He is the inventor of prazosin (Minipress®) and trimazosin (Cardovar®), major prototypical agents for the treatment of hypertension and prostatic hyperplasia, and led the discovery efforts leading to the development of sulprostone (Nalador®), a prostaglandin analog licensed to Schering AG for obstetric and gynecological use, and pirbuterol (Maxair®) , a ß-adrenergic agonist brochodilator licensed to 3M Pharmaceuticals.He received the Pharmaceutical Manufacturers Association (PMA) Drug Discoverers Award for pioneering work on the discovery of prazosin and subsequent drug discovery leadership, and has been named inventor or co-inventor on approximately 100 issued U.S. patents.

Hans-Jürgen Hess, Ph.D.

Former Vice President of Medicinal Products, Research, Pfizer

Hans-Jürgen Hess, Ph.D., Formerly Vice President of Medicinal Products Research at Pfizer, Inc. led for many years their drug discovery efforts in the United States and built and directed the Pfizer drug discovery operations in Japan. He received the Drug Discoverer's Award of the Pharmaceutical Manufacturers Association for his pioneering work on the discovery of prazosin (Minipress) and subsequent drug discovery leadership, and is named an inventor on approximately 100 issued U.S. patents.

Hans-Jurgen Hess, Ph.D.Hans-Jurgen Hess was Vice President of Medicinal Products Research at Pfizer, leading the Pfizer Medicinal Chemistry effort and affiliated functions in the U.S. for many years.He also established and led the Pfizer drug discovery operations in Japan.He is the inventor of prazosin (Minipress,) and trimazosin (Cardovar,), major prototypical agents for the treatment of hypertension and prostatic hyperplasia, and led the discovery efforts leading to the development of sulprostone (Nalador,), a prostaglandin analog licensed to Schering AG for obstetric and gynecological use, and pirbuterol (Maxair,), a b-adrenergic agonist bronodilator licensed to 3M Pharmaceuticals.He received the Pharmaceutical Manufacturers Association (PMA) Drug Discoverers Award for pioneering work on the discovery of prazosin and subsequent drug discovery leadership, and has been named inventor or co-inventor on approximately 100 issued U.S. patents.

The Pintex Scientific Advisory Board also includes Dr. Brian Druker, Howard Hughes Medical Investigator, discoverer of Gleevec in collaboration with Novartis; Dr. Daniel Von Hoff, Director of the Arizona Cancer Center; Dr. Tony Hunter, a leader in the field of cellular signaling biology at the Salk Institute; Dr. Hans Hess, formerly Vice President of Chemistry at Pfizer; Dr. Jack Chabala, formerly Vice President of Chemistry at Merck; Dr. Hans Fliri, former head of Early Lead Discovery at Aventis; Dr. Joseph Noel, a world-renowned crystallographer at Salk; Dr. Gunter Fischer, preeminent enzymologist at the Max-Planck Institute; and Dr. Gordon Gill, Dean of Scientific Affairs at the University of California, San Diego.

BRANFORD, Conn., Oct. 4 /PRNewswire/ -- Cellular Genomics Inc. (CGI, http://www.cellulargenomics.com/) today announced that Hans Hess, Ph.D., and Jan Wasley, Ph.D., have been appointed to the Company's Scientific Advisory Board.
...
Dr. Hess is a former Vice President of Medicinal Products Research at Pfizer, Inc., and Dr. Wasley is the President of Simpharma, LLC, a drug discovery consulting firm with an international client base.
...
Dr. Hess was Vice President of Medicinal Products Research at Pfizer, leading the Pfizer Medicinal Chemistry effort and affiliated functions in the U.S. for many years.He also established and led the Pfizer drug discovery operations in Japan.He is the inventor of prazosin (Minipress(R)) and trimazosin (Cardovar(R)), major prototypical agents for the treatment of hypertension and prostatic hyperplasia, and headed the discovery efforts leading to the development of sulprostone (Nalador(R)), a prostaglandin analog licensed to Schering AG for obstetric and gynecological use, and pirbuterol (Maxair(R)), a beta-adrenergic agonist bronchodilator licensed to 3M Pharmaceuticals.He received the Pharmaceutical Manufacturers Association (PMA) Drug Discoverers Award for pioneering work on the discovery of prazosin and subsequent drug discovery leadership, and has been named inventor or co- inventor on approximately 100 issued U.S. patents.

"CGI has unique and compelling chemical genetic technologies for kinase drug discovery," said Dr. Hess."I am very much looking forward to working with their team as it moves forward in its drug discovery efforts."